ERBB2 and triple-negative breast carcinoma: Our stratified analysis, which accounted for factors such as age, menopausal status, tumor size, family history, clinical stage, lymph node metastasis, estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 status, triple-negative breast cancer prevalence, P53 status, and BRCA1/2 status, revealed no significant correlation between these SNPs and PFS in breast cancer patients (P > 0.05).